269 related articles for article (PubMed ID: 32845591)
1. Fixed Combination Calcipotriene and Betamethasone Dipropionate (Cal/BD) Foam for Beyond-Mild Psoriasis: A Possible Alternative to Systemic Medication.
Kircik L; Stein Gold L; Teng J; Moore A; Cantrell W; Alonso-Llamazares J; Koo J
J Drugs Dermatol; 2020 Aug; 19(8):723-732. PubMed ID: 32845591
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam With Apremilast for Moderate Plaque Psoriasis.
Kircik LH; Schlesinger TE; Tanghetti E
J Drugs Dermatol; 2020 Sep; 19(9):874-880. PubMed ID: 33026749
[TBL] [Abstract][Full Text] [Related]
3. A Cost-utility Analysis of Calcipotriol/Betamethasone Dipropionate Aerosol Foam versus Ointment for the Topical Treatment of Psoriasis Vulgaris in Sweden.
Duvetorp A; Levin LÅ; Engerstedt Mattsson E; Ryttig L
Acta Derm Venereol; 2019 Apr; 99(4):393-399. PubMed ID: 30628631
[TBL] [Abstract][Full Text] [Related]
4. Treating Scalp Psoriasis with Calcipotriene/Betamethasone Dipropionate Fixed-dose Combination Cutaneous Foam: Review of Phase 2 Data.
Petersen B; Lebwohl M
J Drugs Dermatol; 2020 Aug; 19(8):784-786. PubMed ID: 32820879
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness comparison and incremental cost-per-responder analysis of calcipotriene 0.005%/betamethasone dipropionate 0.064% foam vs. halobetasol 0.01%/tazarotene 0.045% lotion for plaque psoriasis: a matching-adjusted indirect comparative analysis.
Wu JJ; Hansen JB; Patel DS; Nyholm N; Veverka KA; Swensen AR
J Med Econ; 2020 Jun; 23(6):641-649. PubMed ID: 31985301
[No Abstract] [Full Text] [Related]
6. Calcipotriol plus betamethasone dipropionate aerosol foam vs. apremilast, methotrexate, acitretin or fumaric acid esters for the treatment of plaque psoriasis: a matching-adjusted indirect comparison.
Bewley AP; Shear NH; Calzavara-Pinton PG; Hansen JB; Nyeland ME; Signorovitch J
J Eur Acad Dermatol Venereol; 2019 Jun; 33(6):1107-1115. PubMed ID: 30472749
[TBL] [Abstract][Full Text] [Related]
7. Twice-weekly topical calcipotriene/betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52 weeks (PSO-LONG trial).
Lebwohl M; Kircik L; Lacour JP; Liljedahl M; Lynde C; Mørch MH; Papp KA; Perrot JL; Gold LS; Takhar A; Thaçi D; Warren RB; Wollenberg A
J Am Acad Dermatol; 2021 May; 84(5):1269-1277. PubMed ID: 32950546
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Calcipotriene Plus Betamethasone Dipropionate Aerosol Foam in Patients With Psoriasis Vulgaris--a Randomized Phase III Study (PSO-FAST).
Leonardi C; Bagel J; Yamauchi P; Pariser D; Xu Z; Olesen M; Østerdal ML; Stein Gold L
J Drugs Dermatol; 2015 Dec; 14(12):1468-77. PubMed ID: 26659941
[TBL] [Abstract][Full Text] [Related]
9. Superior efficacy of calcipotriene and betamethasone dipropionate aerosol foam versus ointment in patients with psoriasis vulgaris--A randomized phase II study.
Koo J; Tyring S; Werschler WP; Bruce S; Olesen M; Villumsen J; Bagel J
J Dermatolog Treat; 2016; 27(2):120-7. PubMed ID: 26444907
[TBL] [Abstract][Full Text] [Related]
10. The Aerosol Foam Formulation of the Fixed Combination Calcipotriene Plus Betamethasone Dipropionate Improves the Health-Related Quality of Life in Patients With Psoriasis Vulgaris: Results from the Randomized PSO-FAST Study.
Leonardi C; Bagel J; Yamauchi P; Pariser D; Xu Z; Moller A; Osterdal ML; Stein Gold L
J Drugs Dermatol; 2016 Aug; 15(8):981-7. PubMed ID: 27537999
[TBL] [Abstract][Full Text] [Related]
11. Calcipotriene plus betamethasone dipropionate in aerosol foam formulation: will this effective treatment for mild-to-moderate psoriasis change clinical practice?
Giovene GL; Giacomelli L;
G Ital Dermatol Venereol; 2018 Dec; 153(6):872-876. PubMed ID: 30261718
[TBL] [Abstract][Full Text] [Related]
12. Fixed-Combination Calcipotriene Plus Betamethasone Dipropionate Aerosol Foam Is Well Tolerated in Patients with Psoriasis Vulgaris: Pooled Data from Three Randomized Controlled Studies.
Menter A; Gold LS; Koo J; Villumsen J; Rosén M; Lebwohl M
Skinmed; 2017; 15(2):119-124. PubMed ID: 28528605
[TBL] [Abstract][Full Text] [Related]
13. Safety of calcipotriene and betamethasone dipropionate foam for the treatment of psoriasis.
Amat-Samaranch V; Puig L
Expert Opin Drug Saf; 2020 Apr; 19(4):423-432. PubMed ID: 32243212
[No Abstract] [Full Text] [Related]
14. Aerosol Foam Formulation of Fixed Combination Calcipotriene Plus Betamethasone Dipropionate is Highly Efficacious in Patients With Psoriasis Vulgaris: Pooled Data From Three Randomized Controlled Studies.
Stein Gold L; Lebwohl M; Menter A; Villumsen J; Rosen M; Koo J
J Drugs Dermatol; 2016 Aug; 15(8):951-7. PubMed ID: 27537995
[TBL] [Abstract][Full Text] [Related]
15. Patient-Reported Satisfaction With the Fixed Combination Calcipotriene/Betamethasone Dipropionate Foam for Plaque Psoriasis.
Gorelick J; Cantrell W; Kucera K; Veverka KA; Gooding K
J Drugs Dermatol; 2018 Aug; 17(8):880-884. PubMed ID: 30124727
[TBL] [Abstract][Full Text] [Related]
16. Four-Week Daily Calcipotriene/Betamethasone Dipropionate Foam Is Highly Efficacious in Patients With Psoriasis (PSO-LONG Lead-in Phase).
Warren RB; Gold M; Gooderham M; Kircik LH; Lacour JP; Laws P; Liljedahl M; Lynde C; Mørch MH; Sondermann W; Thaçi D
J Drugs Dermatol; 2021 Apr; 20(4):436-441. PubMed ID: 33852252
[TBL] [Abstract][Full Text] [Related]
17. A cost-effectiveness analysis of calcipotriol plus betamethasone dipropionate aerosol foam versus gel for the topical treatment of plaque psoriasis.
Foley P; Garrett S; Ryttig L
Curr Med Res Opin; 2018 Jul; 34(7):1277-1283. PubMed ID: 29336190
[TBL] [Abstract][Full Text] [Related]
18. Apremilast with Add-On Calcipotriene/Betamethasone Dipropionate for Treating Moderate to Severe Plaque Psoriasis.
Bagel J; Nelson E; Riley C; Hetzel A
J Drugs Dermatol; 2020 Dec; 19(12):1149-1155. PubMed ID: 33346509
[TBL] [Abstract][Full Text] [Related]
19. Calcipotriol/betamethasone dipropionate aerosol foam in the treatment of psoriasis: new perspectives for the use of an innovative topical treatment from real-life experience.
Fabbrocini G; Dauden E; Jalili A; Bewley A
G Ital Dermatol Venereol; 2020 Apr; 155(2):212-219. PubMed ID: 32394674
[TBL] [Abstract][Full Text] [Related]
20. Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam in Patients with Moderate-to-Severe Psoriasis: Sub-Group Analysis of the PSO-ABLE Study.
Paul C; Leonardi C; Menter A; Reich K; Gold LS; Warren RB; Møller A; Lebwohl M
Am J Clin Dermatol; 2017 Jun; 18(3):405-411. PubMed ID: 28236223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]